Can the <scp>CHA<sub>2</sub>DS<sub>2</sub>‐VA</scp> schema be used to decide on anticoagulant therapy in Aboriginal and other Australians with non‐valvular atrial fibrillation?

Hung, Joe; Kelty, Erin; Nedkoff, Lee; Thompson, Sandra C.; Katzenellenbogen, Judith M.

doi:10.1111/imj.15282

Cited by 2 publications

(1 citation statement)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our results should be reproduced in this population to gain generalizable recommendations across ethnic populations. 26,27 Second, the observational nature of the study necessitates that the conclusions only relate to associations and no causal relations. In relation to this limitation, efficacy of anticoagulant therapy cannot be assessed from an observational study design.…”

Section: Discussionmentioning

confidence: 99%

Arterial Thromboembolism in Patients With Atrial Fibrillation and CHA ₂ DS ₂ -VASc Score 1: A Nationwide Study

Østergaard,

Olesen,

Petersen

et al. 2024

Circulation

View full text Add to dashboard Cite

BACKGROUND: Oral anticoagulation is suggested in patients with atrial fibrillation and a CHA 2 DS 2 -VASc score ≥1 (congestive heart failure, hypertension, age ≥75 years, diabetes, stroke, vascular disease, age 65–74 years, and sex score). To assess granular differences within CHA 2 DS 2 -VASc 1, the incidence of arterial thromboembolism according to CHA 2 DS 2 -VASc 1 subgroups was examined. METHODS: The Danish National Patient Registry and the Danish Prescription Registry linked nationally to identify patients with atrial fibrillation from 2000 to 2021 without oral anticoagulation and categorized according to CHA 2 DS 2 -VASc score: CHA 2 DS 2 -VASc 0 (male and female subjects); CHA 2 DS 2 -VASc 1 (hypertension, heart failure, diabetes, vascular disease, and age 65–74 years); or CHA 2 DS 2 -VASc 2 (age ≥75 years without other risk factors). Female sex was not considered a risk factor in any risk group. The outcome was arterial thromboembolism (ischemic stroke, embolism of extremity, or transient cerebral ischemia). Study groups were compared using Cox regression analysis. RESULTS: We included 26 701 patients with a CHA 2 DS 2 -VASc 0 score; 22 915 with CHA 2 DS 2 -VASc 1 (1483 patients with heart failure, 9066 with hypertension, 843 with diabetes, 770 with vascular disease, and 10 753 who were 65 to 74 years of age); and 14 525 patients with CHA 2 DS 2 -VASc 2 (≥75 years of age without other risk factors). With a median of 1 year of observation time, the cumulative incidence of arterial thromboembolism was 0.6% (n=154 [95% CI, 0.6%–0.8%]), 1.4% (n=16 [95% CI, 0.8%–2.2%]), 1.9% (n=141 [95% CI, 1.6%–2.2%]), 1.7% (n=12 [95% CI, 0.9%–2.9%]), 2.0% (n=13 [95% CI, 1.1%–3.4%]), 2.3% (n=187 [95% CI, 2.0%–2.7%]), and 4.4% (n=533 [95% CI, 4.1%–4.8%]) for CHA 2 DS 2 -VASc 0, heart failure, hypertension, diabetes, vascular disease, age 65 to 74 years (CHA 2 DS 2 -VASc 1), and age ≥75 years (CHA 2 DS 2 -VASc 2), respectively. No statistically significant difference was identified among subgroups of CHA 2 DS 2 -VASc 1 ( P =0.15 for difference). CONCLUSIONS: For patients with atrial fibrillation, all subgroups of CHA 2 DS 2 -VASc 1 were associated with lower incidence of arterial thromboembolism compared with age ≥75 years without other risk factors (ie, CHA 2 DS 2 -VASc 2) and a higher incidence compared with CHA 2 DS 2 -VASc 0. No statistically significant difference was identified between the subgroups of CHA 2 DS 2 -VASc 1. These findings support current recommendations that patients within this intermediate risk group could be identified with a similar risk of arterial thromboembolism.

show abstract

Section: Discussionmentioning

confidence: 99%

Arterial Thromboembolism in Patients With Atrial Fibrillation and CHA ₂ DS ₂ -VASc Score 1: A Nationwide Study

Østergaard,

Olesen,

Petersen

et al. 2024

Circulation

View full text Add to dashboard Cite

show abstract

Long-Term Pattern and Associated Costs of Re-hospitalisations in Patients After Index Atrial Fibrillation Admission in Western Australia, 2011–2017

Weber,

Hung,

Atkins

et al. 2024

Heart, Lung and Circulation

View full text Add to dashboard Cite

Can the CHA₂DS₂‐VA schema be used to decide on anticoagulant therapy in Aboriginal and other Australians with non‐valvular atrial fibrillation?

Cited by 2 publications

References 21 publications

Arterial Thromboembolism in Patients With Atrial Fibrillation and CHA ₂ DS ₂ -VASc Score 1: A Nationwide Study

Arterial Thromboembolism in Patients With Atrial Fibrillation and CHA ₂ DS ₂ -VASc Score 1: A Nationwide Study

Long-Term Pattern and Associated Costs of Re-hospitalisations in Patients After Index Atrial Fibrillation Admission in Western Australia, 2011–2017

Contact Info

Product

Resources

About

Can the CHA2DS2‐VA schema be used to decide on anticoagulant therapy in Aboriginal and other Australians with non‐valvular atrial fibrillation?

Cited by 2 publications

References 21 publications

Arterial Thromboembolism in Patients With Atrial Fibrillation and CHA 2 DS 2 -VASc Score 1: A Nationwide Study

Arterial Thromboembolism in Patients With Atrial Fibrillation and CHA 2 DS 2 -VASc Score 1: A Nationwide Study

Long-Term Pattern and Associated Costs of Re-hospitalisations in Patients After Index Atrial Fibrillation Admission in Western Australia, 2011–2017

Contact Info

Product

Resources

About

Can the CHA₂DS₂‐VA schema be used to decide on anticoagulant therapy in Aboriginal and other Australians with non‐valvular atrial fibrillation?

Arterial Thromboembolism in Patients With Atrial Fibrillation and CHA ₂ DS ₂ -VASc Score 1: A Nationwide Study

Arterial Thromboembolism in Patients With Atrial Fibrillation and CHA ₂ DS ₂ -VASc Score 1: A Nationwide Study